Skip to main content
Top
Published in: Supportive Care in Cancer 6/2020

01-06-2020 | Prostate Cancer | Original Article

Impact of the antifermentative diet during radiotherapy for prostate cancer in elderly, SÃO Paulo, Brazil

Authors: Érica Line de Oliveira Pedron, Rita de Cássia de Aquino, Claudia Borin da Silva

Published in: Supportive Care in Cancer | Issue 6/2020

Login to get access

Abstract

Objective

Assess the impact of the antifermentative diet on the dietary intake and body composition of elderly prostate cancer patients in radiotherapy.

Methods

Observational and prospective study involving 45 men aged 60 years or older, receiving radiotherapy for prostate cancer treatment. The dietary intake was assessed at four times during radiotherapy: onset (TPre), between the 11th and 16th day (T1), between the 24th and 28th day (T2), and on the last day (TLast). The body composition was assessed before and on the last day of radiotherapy, by means of the body weight and height, mid-arm circumference, triceps and subscapular skin folds, phase angle, resistance, and reactance. The data were statistically treated, considering a 5% significance level.

Results

The intake of energy, dietary fibers, and some nutrients decreased during the radiotherapy (p < 0.05). The intake of vitamins E, B1, B2, and folate, of the minerals calcium, magnesium, potassium, sodium, and phosphorus, and of the amino acid leucine dropped when the four assessment times were compared (p < 0.05). As regards the body composition, an impact was observed at the end of the radiotherapy, with lower body weight, arm circumference, subscapular cutaneous fold, phase angle and reactance (p < 0.05).

Conclusion

The antifermentative diet negatively influenced the food consumption and body composition of elderly patients submitted to radiotherapy for prostate cancer.
Literature
16.
go back to reference Higuera-Pulgar I, Ribed A, Carrascal-Fabian ML, Bretón-Lesmes I, Romero-Jiménez RM, Cuerda-Compes C, Velasco-Gimeno C, Camblor-Álvarez M, García-Peris P (2015) Ingesta dietética y estado nutricional de pacientes oncológicos que inician tratamiento com inhibidores tirosina quisana. Nutr Hosp 32(3):1200–1207 https://doi.org/10.3305/nh.2015.32.3.9315 CrossRefPubMed Higuera-Pulgar I, Ribed A, Carrascal-Fabian ML, Bretón-Lesmes I, Romero-Jiménez RM, Cuerda-Compes C, Velasco-Gimeno C, Camblor-Álvarez M, García-Peris P (2015) Ingesta dietética y estado nutricional de pacientes oncológicos que inician tratamiento com inhibidores tirosina quisana. Nutr Hosp 32(3):1200–1207 https://​doi.​org/​10.​3305/​nh.​2015.​32.​3.​9315 CrossRefPubMed
18.
19.
go back to reference Silva HGV, Andrade CF, Moreira ASB (2014) Dietary intake and nutritional status in cancer patients: comparing adults and older adults. Nutr Hosp 29:907–912 Silva HGV, Andrade CF, Moreira ASB (2014) Dietary intake and nutritional status in cancer patients: comparing adults and older adults. Nutr Hosp 29:907–912
30.
go back to reference Bourdel-Marchasson I, Diallo A, Bellera C, Blanc-Bisson C, Durrieu J, Germain C, Mathoulin-Pélissier S, Soubeyran P, Rainfray M, Fonck M, Doussau A (2016) One-year mortality in older patients with cancer: development and external validation of an MNA-based prognostic score. PLoS One 11(2). https://doi.org/10.1371/journal.pone.0148523 Bourdel-Marchasson I, Diallo A, Bellera C, Blanc-Bisson C, Durrieu J, Germain C, Mathoulin-Pélissier S, Soubeyran P, Rainfray M, Fonck M, Doussau A (2016) One-year mortality in older patients with cancer: development and external validation of an MNA-based prognostic score. PLoS One 11(2). https://​doi.​org/​10.​1371/​journal.​pone.​0148523
33.
Metadata
Title
Impact of the antifermentative diet during radiotherapy for prostate cancer in elderly, SÃO Paulo, Brazil
Authors
Érica Line de Oliveira Pedron
Rita de Cássia de Aquino
Claudia Borin da Silva
Publication date
01-06-2020
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 6/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-05187-0

Other articles of this Issue 6/2020

Supportive Care in Cancer 6/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine